RELIEF THERAPEUTICS : announces significant difference in its 2018 half year financial results compared with 2017

Geneva, Switzerland, 27 September 2018

RELIEF THERAPEUTICS Holding AG ('Relief', the 'Company') announces, before the publication of its financial results, significant difference of its results for the half-year ended 30 June 2018 compared with the same period in 2017. Indeed, Relief generated a net loss of 365 thousands CHF for the period between the 1^st of January 2018 and the 30^th of June 2018 compared to a net loss of 1'069 thousands CHF for the same period in 2017. EBITDA was also reduced for the half-year ended 30 June 2018 to 420 thousands CHF compared to 1'048 thousands CHF for the same period in 2017. This difference is mainly the results of the drastic financial restriction that Relief applied to its expenses as announced in 2017 comprising cuts in personnel, operational and administrative expenses while continuing to commit to grow its business.

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two first candidates are Aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (Atexakin alfa) for the treatment of peripheral neuropathy (to enter Phase II). Aviptadil development in sarcoidosis addresses the orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, The current priority indication for Atexakin is to alleviate peripheral diabetic neuropathy, a market that is estimated to reach $4.1 billion in 2019 (source Datamonitor). In addition to these initial drug candidates, Relief has initiate a strategic collaboration with Genclis in April 2018 in order to co-develop and commercialize products arising from their disruptive technology.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.comor contact investor relations at:
RELIEF THERAPEUTICS Holding AG
Investor Relations
Tel: [phone]

[e-mail]
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise